Injection for adults with allergic rhinitis
Treatments studied
Part of Ear, nose & throat, Immune system & allergy, Lungs & breathing clinical trials.
This study tests an investigational injection (called JYB1904) to see if it helps reduce allergy symptoms from dust mites, pet dander, and other indoor allergens. It is for adults with moderate to severe allergic rhinitis (hay fever) who still have symptoms despite using a daily nasal steroid spray.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have had allergic rhinitis (hay fever) symptoms for at least 2 years.
- You must have been using a prescription nasal spray (corticosteroid spray) regularly for at least 4 weeks before starting the study.
- You must have a positive allergy test to indoor allergens (like dust mites or pet dander) within the past year.
- You need to be willing to fill out a daily symptom diary during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injection (JYB1904) that may help control allergic reactions. It is for teenagers aged 12 to 17 who have had allergic conditions, to see if the drug is safe and how it works in this age group.
This study tests an investigational injection (GR1802) that may help reduce seasonal allergy symptoms when standard allergy medications aren't enough. If you qualify, you'll receive the injection during the pollen season to see if it improves your sneezing, runny nose, and itchy eyes.
This study tests a new injection called MG-K10 for people with moderate-to-severe seasonal hay fever that isn't well controlled by standard treatments like nasal sprays or antihistamines. The goal is to see if it can reduce your allergy symptoms over the pollen season.
This trial tests an experimental antibody (IL4Rα monoclonal antibody) for people with seasonal allergic rhinitis (hay fever) that is not well controlled by standard treatments like nasal steroid sprays. The goal is to see if this new treatment can help reduce allergy symptoms during pollen season.
This trial tests a new medicine called DW1807 for people who have both year-round allergies (like dust mites or pet dander) and asthma. It aims to see if it helps control nasal symptoms and is safe to use.
This trial tests an under-the-tongue tablet for people with dust mite allergies causing moderate to severe nasal symptoms or mild-to-moderate asthma. The goal is to see if it improves symptoms and can replace or reduce the need for allergy medicines.
Hear when a new Perennial Allergic Rhinitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.